Science

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Patrick Forde/Facebook

Mar 11, 2025, 13:12

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, shared an article by Anwen Xiong, et al. on X:

“Now published!

PD-1 VEGF bispecific doubles PFS in 1st line advanced non-small cell lung cancer.

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China – The Lancet.”

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.

Authors: Anwen Xiong, et al.

Patrick Forde: PD-1 VEGF bispecific doubles PFS in 1st line advanced NSCLC

Anwen Xiong cancer China fight against cancer Global fight against cancer HARMONi-2 ivonescimab Johns Hopkins University non small cell lung cancer NSCLC OncoDaily Oncology Patrick Forde pembrolizumab Sidney Kimmel Comprehensive Cancer Center The Lancet

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial